Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes

Dolutegravir in antiretroviral-naive adults with HIV-1

(2013) Hans-Jürgen Stellbrink et al.   AIDS

Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir

(2013) Wei Huang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248

(2013) Adriana Andrade et al.   JOURNAL OF INFECTIOUS DISEASES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Inhibition of Dual/Mixed Tropic HIV-1 Isolates by CCR5-Inhibitors in Primary Lymphocytes and Macrophages

(2013) Matteo Surdo et al.   PLoS One

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

(2012) Carolina Garrido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Virologic evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens

(2012) Matthew D Marsden et al.   ANTIVIRAL THERAPY

Novel therapeutic strategies targeting HIV integrase

(2012) Peter K Quashie et al.   BMC Medicine

Emerging patterns and implications of HIV-1 integrase inhibitor resistance

(2012) Anna Maria Geretti et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Dolutegravir for the treatment of HIV

(2012) Christine Katlama et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

(2012) Edwin DeJesus et al.   HIV CLINICAL TRIALS

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens

(2012) HL Nguyen et al.   HIV MEDICINE

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

(2012) Mark R. Underwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo

(2012) S. Fransen et al.   JOURNAL OF VIROLOGY

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Structure and Dynamics of the G121V Dihydrofolate Reductase Mutant: Lessons from a Transition-State Inhibitor Complex

(2012) Randall V. Mauldin et al.   PLoS One

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143

(2011) Mathieu Métifiot et al.   AIDS

Single Mutations in HIV Integrase Confer High-Level Resistance to Raltegravir in Primary Human Macrophages

(2011) Matthew D. Marsden et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes

(2011) Fernanda Scopelliti et al.   ANTIVIRAL RESEARCH

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

(2011) S. Hare et al.   MOLECULAR PHARMACOLOGY

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

(2010) José Moltó et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption

(2010) F. Canducci et al.   CLINICAL MICROBIOLOGY AND INFECTION

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

(2010) Hiroyu Hatano et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay

(2010) Zuleika Michelini et al.   JOURNAL OF VIROLOGICAL METHODS

The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions

(2010) Sandrine Reigadas et al.   PLoS One

Macrophage signaling in HIV-1 infection

(2010) Georges Herbein et al.   Retrovirology

Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo

(2009) C. Goffinet et al.   JOURNAL OF VIROLOGY

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

(2009) Joy Y Feng et al.   Retrovirology

Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages

(2009) Sebastiaan M. Bol et al.   VIROLOGY

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

(2008) Vincenzo Summa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donor variability in HIV binding to peripheral blood mononuclear cells

(2008) Joshua J Anzinger et al.   Virology Journal

Human macrophages support persistent transcription from unintegrated HIV-1 DNA

(2007) Jeremy Kelly et al.   VIROLOGY